Maravai LifeSciences Holdings Future Growth
Future criteria checks 3/6
Maravai LifeSciences Holdings is forecast to grow earnings and revenue by 126.4% and 5.3% per annum respectively. EPS is expected to grow by 128.9% per annum. Return on equity is forecast to be 0.2% in 3 years.
Key information
126.4%
Earnings growth rate
128.9%
EPS growth rate
Life Sciences earnings growth | 0% |
Revenue growth rate | 5.3% |
Future return on equity | 0.2% |
Analyst coverage | Good |
Last updated | 23 Feb 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 347 | 19 | 102 | N/A | 5 |
12/31/2025 | 302 | 16 | 71 | N/A | 12 |
12/31/2024 | 272 | 0 | 58 | N/A | 11 |
12/31/2023 | 289 | -119 | N/A | N/A | N/A |
9/30/2023 | 420 | 25 | 163 | 218 | N/A |
6/30/2023 | 544 | 75 | 268 | 314 | N/A |
3/31/2023 | 718 | 153 | 437 | 459 | N/A |
12/31/2022 | 883 | 220 | 519 | 536 | N/A |
9/30/2022 | 907 | 238 | 479 | 495 | N/A |
6/30/2022 | 920 | 248 | 479 | 491 | N/A |
3/31/2022 | 895 | 226 | 478 | 493 | N/A |
12/31/2021 | 799 | 182 | 354 | 369 | N/A |
9/30/2021 | 669 | 150 | 371 | 389 | N/A |
6/30/2021 | 552 | 127 | 308 | 335 | N/A |
3/31/2021 | 381 | 78 | 155 | 181 | N/A |
12/31/2020 | 284 | 77 | 127 | 152 | N/A |
12/31/2019 | 143 | -8 | 7 | 24 | N/A |
12/31/2018 | 124 | -18 | -4 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRVI * is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (7.7%).
Earnings vs Market: MRVI * is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MRVI * is expected to become profitable in the next 3 years.
Revenue vs Market: MRVI *'s revenue (5.3% per year) is forecast to grow slower than the MX market (6.1% per year).
High Growth Revenue: MRVI *'s revenue (5.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MRVI *'s Return on Equity is forecast to be low in 3 years time (0.2%).